Hot Investor Profile: Canada-Based VC Invests in Pre-Seed and Seed Stage Companies Across the Globe in All Areas of Life Sciences & Healthcare

18 Jul

A venture capital firm headquartered in Canada likes to be an early-believer and invest in early-stage companies in niche areas that are often overlooked. Interested areas include, but are not limited to, healthcare, food tech, education, clean tech, software and more. The firm only invests in Pre-Seed and Seed stage companies and will typically allocate between $25k-500k USD. The firm has co-led and led rounds, but mainly acts as a co-investor and is open to global companies. 
 
The firm is sector-agnostic and in terms of life science, will invest in devices, health tech, drug discovery, and diagnostics. The firm invests in companies that are pre-phase I and/or in-development. The firm is also indication agnostic. 
 
The firm strongly emphasizes and looks for a dedicated and full-time team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

RESI JPM Moves to the San Francisco Marriott Marquis!

18 Jul

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

The RESI JPM conference is set to make waves in 2025 with its exciting new location at the San Francisco Marriott Marquis during the highly anticipated JP Morgan Healthcare week. This move to a more central and modern venue, used by numerous large pharmas and investors for meeting space as well, promises to elevate the conference experience for attendees.

The San Francisco Marriott Marquis, located in the heart of downtown San Francisco, offers a prime location for conference-goers. Its central position puts attendees within easy reach of The Westin St. Francis, Union Square, and other key areas of interest during the bustling JP Morgan Healthcare week. This strategic location will facilitate networking opportunities and allow participants to navigate between various events happening throughout the city seamlessly.

The Marriott Marquis is renowned for its state-of-the-art facilities, making it an ideal choice for hosting a successful conference. The hotel boasts spacious meeting rooms equipped with cutting-edge technology, ensuring smooth presentations and interactive sessions. The venue’s modern amenities and updated infrastructure will support the diverse needs of the RESI JPM conference, from large-scale presentations to intimate networking events.

The move to this updated and centrally located venue reflects RESI’s commitment to providing the best possible environment for early-stage life science companies and investors to connect. With its proximity to other JP Morgan Healthcare week events, the new location will likely attract even more attendees, potentially surpassing the anticipated 500+ early-stage investors from previous years.

By choosing the San Francisco Marriott Marquis, RESI JPM 2025 is poised to offer an exceptional conference experience. The combination of a central location, modern facilities, and the vibrant atmosphere of JP Morgan Healthcare week sets the stage for a highly successful and productive event, further cementing RESI’s position as a key player in the life science investment landscape.

Registration for RESI JPM is open and Super Early Bird rates are in effect, saving attendees $500.

Register-now-button-new

RESI-SF-2025-Banner-1100px

Hot Investor Profile: USA-Based VC Firm Engages in Series A and B Financings in Medical Devices, Diagnostics, and Digital Health Sectors

11 Jul

A venture capital firm founded in 2020 and based in the US, is seeking opportunities in the medical devices and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with initial check sizes between 1 – 3 million USD. The firm prefers to lead/co-lead the financing rounds but is open to co-investing. The firm is focused on companies located in North America and Israel. 
 
The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises. 
 
The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Transatlantic Venture Fund Invests in US and Europe-Based Therapeutics & Medical Device Companies

11 Jul

An international family of venture capital funds invests in early-stage, high-growth life science and health technology companies in the US, UK, and Europe. The firm manages both a US and EU based fund. The EU fund primarily provides Series A financing in the range of £2-5M. The EU fund is actively seeking new investment opportunities in the UK and Europe, and the US fund invests in all of US. 
 
The firm is currently seeking to invest in novel early stage biopharma and medical devices opportunities. The firm is opportunistic in terms of subsectors and indications. 
 
The firm requests a board seat in each portfolio company. The firm invests in management teams who are highly driven and tenacious problem solvers.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: USA-Based VC Invests Up to $10M in Devices, Advanced Materials, Platform Technologies, and More Across the Globe

11 Jul

A venture capital firm with multiple offices in the US partners with and invests in entrepreneurs who are developing breakthrough products leveraging the convergence of biology and/or hardware with advanced computation and AI (referred to as Convergent Tech). The firm employs a multi-stage investment strategy, encompassing both seed and venture investment programs, and assist entrepreneurs with recruiting and customer and supply chain business development. The firm is generally a lead investor, and invests up to $10 million per opportunity; the firm also has an active seed fund that invests smaller amounts at earlier development stages. 
 
The firm is invests in life science start-ups developing advanced materials, process, and device technologies that leverage advanced computational approaches such as deep learning, and unique data generation capabilities. Specific areas of interest include drug discovery platforms, manufacturing platforms, drug delivery platforms, non-invasive diagnostics, and sustainability generally. The firm does not invest in pure-play therapeutic clinical development business models. 
 
The firm favors companies with platform technologies and partnership-based business models. The firm has deep expertise in manufacturing and productization. Additionally, LPs include large pharma and medical device manufacturing companies; the firm helps portfolio companies develop relationships with these strategics. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Profile: Leading China-Based Pharma Company Seeks Pre-Clinical and Early Clinical Assets in CNS, Oncology, Metabolic Diseases, and More

11 Jul

A leading pharmaceutical company headquartered in China with integrated R&D, manufacturing, marketing, sales and distribution capabilities. The firm operates as a subsidiary of a publicly traded pharmaceutical company. The firm has a strong pipeline in liver diseases, oncology, respiratory diseases and is one of the top pharmaceutical companies in China within these domains. In addition, the firm has strong interest in CNS diseases, metabolic diseases, etc. With extensive experience and successful records of in and out licensing and co-development ventures with oversea companies, the firm is interested in collaborating with oversea companies whose assets align with its current pipeline and areas of interest. The firm is open to a wide range of partnership and capital structures, including co-development, in/out-licensing, equity investments and acquisitions. The firm is interested in opportunities globally. 
 
The firm is interested in therapeutic assets that align with their areas of focus, which include liver diseases, oncology, respiratory disease, CNS disease, metabolic diseases. The firm is open to various modalities within therapeutics, with a particular emphasis on both large and small molecule drugs. The firm seeks assets ranging from pre-clinical to early-clinical stages (Phase I/Phase Ib), but is also open to considering later-stage assets that align well with their scope of interest. 
 
The firm does not have any specific requirement for the company and the management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Announcing RESI Boston Investor Panel Lineup

11 Jul

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston, scheduled for September 25-27, 2024, is Life Science Nation (LSN)‘s upcoming hybrid event that promises to be a pivotal platform for early-stage deal-making in the life sciences sector. The conference will be held at the Westin Copley Place Hotel, with in-person activities on September 25, followed by two days of virtual partnering on September 26-27.

RESI (Redefining Early Stage Investments) is designed to connect start-ups and early-stage investors across the domains of drugs, devices, diagnostics, and digital health. This event is particularly valuable for fundraising executives seeking to establish connections with investors and licensing partners.

One of RESI’s key features is its investor panels, which offer attendees insights into the latest industry trends and provide guidance on how to effectively communicate with potential partners. These panels serve a dual purpose:

  • They offer valuable industry insights from experienced investors.
  • They provide attendees with opportunities to learn about individual investors and potentially schedule on-site meetings.

The conference caters to companies at various funding stages, from those seeking seed capital ($25K – $2M) to those looking for Series B funding ($10M – $50M). RESI Boston is expected to attract over 300 early-stage life science investors and licensing partners, as well as more than 300 early-stage life science companies.

Check out the panel lineup below and be sure to maximize the benefits of attending RESI Boston, by registering early. Early bird rates, offering a $300 discount, are available until Friday, August 2.

Register-now-button-new

RESI Boston Investor Panels
(September 25)
9:00 ET
Partnering With Pharma Panel
Pharma Seeking Early-Stage Assets
10:00
ET
Angel Investors Panel
Explaining the Process of Engagement
11:00
ET
Digital Health Panel
Accelerating Technologies to Improve Quality of Care
13:00
ET
Early-Stage Therapeutics Panel
Bringing the Newest Therapies to the Clinic
14:00
ET
Diagnostics Panel
Advancements for Personalized Care and Medicine
15:00
ET
Family Offices Panel
Perspectives on Early-Stage Investments
16:00
ET
AI in Healthcare Panel
Investing in the Intersection of Science and Technology

RESI-Boston-2024-September-1100pxw

← Older Entries
Newer Entries →